Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
MBX BiosciencesMBX | Open-market sale10b5-1 plan | 05/08 | 05/11 | 70,003 sh2 trades | $38.36avg. | $2,685,514.9 | −82.6% | |
P. Kent HawrylukPresident & CEO | MBX BiosciencesMBX | Open-market sale | 05/06 | 05/08 | 607 sh | $29.54 | $17,930.78 | −0.1% |
Salomon AzoulayChief Medical Officer | MBX BiosciencesMBX | Open-market sale | 05/06 | 05/08 | 231 sh | $29.54 | $6,823.74 | −1.5% |
P. Kent HawrylukPresident & CEO | MBX BiosciencesMBX | Open-market buy | 03/13 | 03/16 | 18,500 sh | $28.41 | $525,585 | +4.0% |
P. Kent HawrylukPresident & CEO | MBX BiosciencesMBX | Open-market buy | 25/10/20 | 25/10/21 | 20,000 sh | $13.64 | $272,800 | +4.5% |
Steven L. HoerterDirector | MBX BiosciencesMBX | Open-market buy | 25/10/17 | 25/10/20 | 20,000 sh | $13.25 | $265,000 | No record |
James N. Topper10% Owner | MBX BiosciencesMBX | Open-market buy | 25/09/26 | 25/09/30 | 666,666 sh | $18.00 | $11,999,988 | +14.6% |
Patrick J. HeronDirector | MBX BiosciencesMBX | Open-market buy | 25/09/26 | 25/09/30 | 666,666 sh | $18.00 | $11,999,988 | +14.6% |
Fhmls X10% Owner | MBX BiosciencesMBX | Open-market buy | 25/09/26 | 25/09/30 | 666,666 sh | $18.00 | $11,999,988 | +14.6% |
Frazier Life Sciences X10% Owner | MBX BiosciencesMBX | Open-market buy | 25/09/26 | 25/09/30 | 666,666 sh | $18.00 | $11,999,988 | +14.6% |
Fhmls X10% Owner | MBX BiosciencesMBX | Open-market buy | 25/09/26 | 25/09/30 | 666,666 sh | $18.00 | $11,999,988 | +14.6% |
Ora H. PescovitzDirector | MBX BiosciencesMBX | Open-market buy | 25/04/08 | 25/04/10 | 7,693 sh | $5.89 | $45,311.77 | +46.2% |
MBX BiosciencesMBX | Open-market buy | 25/02/14–25/02/18 | 25/02/19 | 190,672 sh4 trades | $10.60avg. | $2,020,755.6 | +34.2% | |
Director | MBX BiosciencesMBX | Open-market buy | 25/02/14–25/02/18 | 25/02/19 | 190,672 sh4 trades | $10.60avg. | $2,020,755.6 | +34.2% |
MBX BiosciencesMBX | Open-market buy | 25/02/14–25/02/18 | 25/02/19 | 190,672 sh4 trades | $10.60avg. | $2,020,755.6 | +34.2% | |
MBX BiosciencesMBX | Open-market buy | 25/02/14–25/02/18 | 25/02/19 | 190,672 sh4 trades | $10.60avg. | $2,020,755.6 | +34.2% | |
P. Kent HawrylukPresident & CEO | MBX BiosciencesMBX | Open-market buy | 25/02/04 | 25/02/05 | 50,000 sh | $10.69 | $534,500 | +12.6% |
MBX BiosciencesMBX | Open-market buy | 24/09/16 | 24/09/17 | 750,000 sh2 trades | $16.00avg. | $12,000,000 | No record | |
Scott D. Sandell10% Owner | MBX BiosciencesMBX | Open-market buy | 24/09/16 | 24/09/17 | 500,000 sh | $16.00 | $8,000,000 | +16.1% |
Forest Baskett10% Owner | MBX BiosciencesMBX | Open-market buy | 24/09/16 | 24/09/17 | 500,000 sh | $16.00 | $8,000,000 | +16.1% |
